$TBPH

Samaha Eli sold $5.8M of TBPH (indirect holdings)

Samaha Eli sold 336,697 indirectly-held shares of Theravance Biopharma, Inc. (TBPH) at an average of $17.20 ($17.00–$17.23, $5.79M total) across 3 trades over 2026-06-29 to 2026-07-01.

Original reporting
SEC EDGAR · Samaha Eli
Published Jul 1, 2026, 11:33 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 1, 2026, 11:35 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$TBPH
Neutral
medium confidence
Mentioned
$TBPH
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TBPHNeutralLow
01

Why it matters

The newest concrete fact is the disclosed open-market sale size, price range, and post-transaction holdings; it may influence short-term sentiment but does not change fundamentals in the text.

02

Market read

Traders may reassess near-term sentiment around TBPH given a large owner’s disclosed sale, but there is no accompanying operational catalyst.

03

What to watch

The transaction is described as indirect holdings and explicitly notes no pre-arranged 10b5-1 plan, which can increase interpretive uncertainty for traders.

Relevance 6/10Novelty 6/10Timing: after-hours/filing date (2026-07-01) for late-June/early-July insider sale window

Background

The article is an SEC Form 4 insider transaction disclosure for Theravance Biopharma, Inc. (TBPH).

Company-level read

Ticker impact

$TBPHNeutralMedium confidence
Context

SEC Form 4 shows 10% owner Samaha Eli sold $5.79M of Theravance Biopharma shares via open-market sales (336,697 shares) in late June/early July.

Expected impact

Likely limited/short-lived impact; watch for follow-through selling or stabilization after the disclosed sale window.

Evidence & confidence

The filing is a primary-source insider transaction with clear size and timing, but it provides no new business, guidance, or regulatory/clinical catalyst.

Market effects

Biopharma insider-sale prints can slightly influence sentiment across small/mid-cap names, but this is company-specific and not sector-wide.

No direct regional spillover indicated; US-listed issuer filing only.

Limited global relevance; no deal, trial, or regulatory action described.

Counterpoint

A sale can be routine liquidity/portfolio rebalancing and does not necessarily signal reduced confidence, especially without a 10b5-1 plan.

Key entities

  • Theravance Biopharma, Inc.

    Subject of the Form 4 insider transaction; 10% owner sold shares totaling ~$5.79M.

  • Samaha Eli

    Reporter/10% owner who executed open-market sales (indirect holdings) between 2026-06-29 and 2026-07-01.

Related articles

$ZYMEHighAI 9/10

USA: Zymeworks acquisisce Theravance Biopharma, focus su YUPELRI per diversificare il portafoglio e accelerare la crescita – Padovanews

Zymeworks Inc. agreed to acquire Theravance Biopharma, adding YUPELRI (revefenacin) for COPD. The deal values Theravance at $17/share, with a $350 million non-recourse note and $219 million cash plus Theravance’s estimated $360 million net cash at closing. YUPELRI U.S. net sales were $266.6M in 2025. Expected close in H2 2026.

$ZYMEHighAI 9/10

Vancouver biotech Zymeworks buying Theravance for US$929M

Zymeworks Inc. (Nasdaq:ZYME) said it will pay $929M in cash to acquire Theravance Biopharma Inc. (Nasdaq:TBPH). The offer is $17 per Theravance share, 3.6% below the prior close. Theravance’s ampreloxetine failed a March trial; its only marketed drug is Yupelri. Deal includes a one-year ampreloxetine monetization split and about $2.5B in Irish tax attributes.